FOLIGRAF 450 IU MULTIDOSE PRE FILLED PEN

Dosage

Children: Refer to specific product guidelines as dosages may vary based on the active ingredient and clinical condition.

Adults: Refer to specific product guidelines as dosages may vary based on the active ingredient and clinical condition.

Mechanism of action

The specific mechanism of action for a concentrated drug depends on the active ingredients present in the formulation. Generally, concentrated drugs exert their effects by interacting with specific receptors or enzymes in the body, altering physiological processes. For example, concentrated analgesics may inhibit cyclooxygenase enzymes, leading to reduced production of prostaglandins, resulting in pain relief. Similarly, concentrated antibiotics may inhibit bacterial cell wall synthesis, leading to bacterial death.

Pharmacodynamics

Pharmacodynamics of concentrated drugs involves understanding the relationship between drug concentration at the site of action and the resulting therapeutic effect. Concentration-dependent effects may be observed, where higher concentrations lead to increased efficacy but also a risk of toxicity. The therapeutic window, which is the range between effective and toxic concentrations, is critical in guiding the safe use of concentrated formulations.

Pharmacokinetics

Pharmacokinetics of concentrated drugs encompasses absorption, distribution, metabolism, and excretion (ADME). Concentrated formulations may have altered pharmacokinetic profiles compared to standard formulations due to their higher potency. Absorption may be faster or more extensive, depending on the formulation. Distribution may be influenced by factors such as lipophilicity and plasma protein binding. Metabolism may occur in the liver, primarily through enzymatic pathways, while excretion typically occurs via renal or biliary routes.

Pregnancy

Consult a healthcare professional before use. Safety in pregnancy has not been established.

Breast-feeding

Consult a healthcare professional before use. Safety during breastfeeding has not been established.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Infertility due to hypogonadotropic hypogonadism
• Assisted reproductive technologies, such as in vitro fertilization (IVF)
• Ovarian stimulation in women undergoing fertility treatments
• Male infertility due to insufficient spermatogenesis

Dosage

Children: Refer to the BNF for Children for appropriate dosing guidelines in paediatric populations.

Adults: Refer to specific clinical guidelines and the BNF for dosing recommendations based on individual patient factors and treatment protocols.

Mechanism of action

Follitropin acts by binding to and activating the follicle-stimulating hormone receptor (FSHR) on the surface of ovarian granulosa cells and testicular Sertoli cells. This activation leads to a cascade of intracellular signaling pathways that promote the growth and maturation of ovarian follicles in women and stimulate spermatogenesis in men, thus facilitating fertility.

Pharmacodynamics

Follitropin enhances the ovarian response to gonadotropin stimulation, leading to increased estradiol production and follicular growth. In males, it stimulates Sertoli cells to support spermatogenesis. The pharmacodynamic effects of follitropin are dose-dependent, with higher doses generally resulting in a greater biological response, although individual responses may vary based on receptor sensitivity and other factors.

Pharmacokinetics

Follitropin is administered via subcutaneous injection, with peak plasma concentrations occurring approximately 12 to 24 hours post-injection. The half-life of follitropin is approximately 2 to 4 hours, but its biological effects last longer due to the continuous stimulation of the FSH receptor. It is primarily eliminated through renal pathways, and its pharmacokinetic profile can be influenced by factors such as patient age, body weight, and renal function.

Contra-indications

• Hypersensitivity to follitropin or any of its excipients
• Primary ovarian failure
• Pituitary or hypothalamic tumors
• Ovarian cysts or enlarged ovaries not due to polycystic ovary syndrome
• Pregnancy

Adverse effects

• Ovarian hyperstimulation syndrome (OHSS)
• Headache
• Abdominal pain
• Nausea
• Injection site reactions
• Multiple pregnancies
• Breast tenderness

Interactions

• Other gonadotropins may have additive effects
• Hormonal contraceptives may reduce the efficacy of follitropin
• Corticosteroids may affect ovarian response

Precautions

• Use with caution in patients with a history of thromboembolic events
• Monitor for signs of OHSS
• Assess ovarian response carefully during treatment
• Consider patient’s psychological state when undergoing fertility treatment

Pregnancy

Follitropin is contraindicated in pregnancy due to potential risks to the fetus.

Breast-feeding

Limited data available; caution is advised when administering to breastfeeding women.

Storage

Store in a refrigerator (2-8 degrees Celsius), do not freeze. Protect from light.

Formulations

• Follitropin alfa (recombinant)
• Follitropin beta (recombinant)